A case for developing North-South partnerships for research in sickle cell disease

Blood

Volumn 105, Issue 3, 2005, Pages 921-923

  Weatherall, David ^a   Hofman, Karen ^b   Rodgers, Griffin ^b   Ruffin, John ^b   Hrynkow, Sharon ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; HEMOGLOBIN S; HYDROXYUREA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PENICILLIN G;

AFRICA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; GENE TECHNOLOGY; GENETIC ASSOCIATION; HUMAN; MEDICAL RESEARCH; MORBIDITY; MORTALITY; NEWBORN SCREENING; PATIENT CARE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; VASCULAR DISEASE;

EID: 12844276479     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-06-2404     Document Type: Review

References (29)

1. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79:704-712.
2. S gene: origins, genetic epidemiology, and epistasis in sickle cell anemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of Hemoglobin. Cambridge, United Kingdom: Cambridge University Press; 2001:711-755.
3. Livingstone FB. Frequencies of Hemoglobin Variants. New York, NY: Oxford University Press; 1985.
4. World Health Organization. Guidelines for the Control of Haemoglobin Disorders. Geneva, Switzerland: World Health Organization; 1994.
5. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics. 1989;84:500-508.
6. Thomas AN, Pattison C, Serjeant GR. Causes of death in sickle-cell disease in Jamaica. Br Med J (Clin Res Ed). 1982;285:633-635.
7. Serjeant GR. Geographic heterogeneity of sickle cell disease. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of Hemoglobin. Cambridge, United Kingdom: Cambridge University Press; 2001:895-905.
8. Gelpi AP. Benign sickle cell disease in Saudi Arabia: survival estimate and population dynamics. Clin Genet. 1979;15:307-310.
9. Davis H, Moore RM Jr, Gergen PJ. Cost of hospitalizations associated with sickle cell disease in the United States. Public Health Rep. 1997;112:40-43.
10. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337:762-769.
11. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986;314:1593-1599.
12. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645-1651.
13. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;333:5-11.
14. Ballas SK. Sickle cell disease: clinical management. Clin Haematol. 1998;11:185-214.
15. Nagel RL, Platt OS. General pathophysiology of sickle cell disease. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of Hemoglobin. Cambridge, United Kingdom: Cambridge University Press; 2001:494-526.
16. Nadeau JH. Modifier genes in mice and humans. Nat Rev Genet. 2001;2:165-174.
17. s-globin gene haplotypes: evidence for an independent Asian origin of the sickle-cell mutation. Am J Hum Genet. 1986;39:239-244.
18. Allison AC. Protection afforded by sickle-cell trait against subtertian malarial infection. Br Med J. 1954;4857:290-294.
19. Hill AVS, Allsopp CEM, Kwiatkowski D, et al. Common west African HLA antigens are associated with protection from severe malaria. Nature. 1991;352:595-600.
20. Weatherall DJ, Clegg JB. Genetic variability in response to infection: malaria and after. Genes Immun. 2002;3:331-337.
21. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001;2:245-255.
22. Hobbs MR, Udhayakumar V, Levesque MC, et al. A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. Lancet. 2002;360:1468-1475.
23. Gladwin MT, Schechter AN. Nitric oxide therapy in sickle cell disease. Semin Hematol. 2001;38:333-342.
24. World Health Organization. Genomics and World Health. Geneva, Switzerland: World Health Organization; 2002.
25. Weatherall DJ. Genomics and global health: time for a reappraisal. Science. 2003;302:597-599.
26. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. 4th ed. Oxford, United Kingdom: Blackwell Science; 2001.
27. Rahimy MC, Gangbo A, Ahouignan G, et al. Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting. Blood. 2003;102:834-838.
28. Akinyanju O. Issues in the management of sickle cell disorders. Arch Ibadan Med. 2001;2:37-41.
29. Keusch GT, Medlin CA. Tapping the power of small institutions. Nature. 2003;422:561-562.